Lung cancer is the leading cause of cancer death in the United States and world-wide causing an estimated 156,940 deaths in 2011, a figure exceeding the combined mortalities from breast, prostate, and colorectal cancers. Despite decades of research, overall 5-year survival has remained at a dismal 15-17%, making it among the most lethal cancers. Because lung cancer develops deep within the chest cavity and typically causes no symptoms until the disease is advanced and incurable, early detection is critical.
Molecular diagnostic screening has numerous clinical applications including early detection, rapid diagnosis, improved prognostic assesssment and prediction of response to therapy. Molecular assays can also be used to develop individualized, treatment options utilizing targeted therapies for lung cancer patients. Current genetic assays are technically complex, expensive, and take too long to return results to clinicians, making them impractical for routine screening. Thus, there is an urgent need for rapid, high-throughput, hight-quality and cost-effective diagnostic assays for lung cancer.
Assays for Lung Cancer
Novel molecular diagnostic assay for lung cancer
Tech ID: / UC Case: SF2011-132
UCSF investigators in the Thoracic Oncology Laboratory have developed a novel multi-gene, high-throughput molecular screening assay for early diagnosis and prognostic assessment of lung cancer. This assay provides results to clinicians within 24 hours. The technology for the assay was validated using fresh-frozen tissue specimens of 96 lung adenocarcinoma patients as well as paraffin-embedded tissues for the selected samples. Plans for further clinical validation studies of this technology are underway using a larger number of fresh-frozen and paraffin-embedded tissues.